A novel and unique pharmacological platform that has led to promising new therapeutic leads.
Advancing Leads From Preclinical to Clinical
Saillant Therapeutics has invented and developed a novel and unique pharmacological platform ST-01, together with corresponding proprietary therapeutic leads. These compounds activate a cellular master regulator, thus controlling adaptive functions in various cells and tissues.
Therapeutic intervention through this regulator mechanism enables the prevention of tissue damage to vital organ systems such as the cardiovascular system and the central nervous system. The same mechanism also effectively inhibits intracellular virus replication.
This unique technology has led to three new therapeutic leads that are currently in preclinical development, in preparation for entering clinical Phase I/I testing.
Ready to Make a Change?
By our full preclinical package, we work together with our partners throughout the process until the commercialization of a drug candidate.